Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
160 hedge funds and large institutions have $555M invested in Eagle Pharmaceuticals, Inc. in 2022 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 55 increasing their positions, 66 reducing their positions, and 17 closing their positions.
3% less capital invested
Capital invested by funds: $573M → $555M (-$17.6M)
1% less funds holding
Funds holding: 162 → 160 (-2)
12% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 17
17% less repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 66
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
95% less call options, than puts
Call options by funds: $24K | Put options by funds: $485K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$10.8M |
| 2 |
DZ Bank
Frankfurt Am Main,
Germany
|
+$7.96M |
| 3 |
Goldman Sachs
New York
|
+$3.38M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$1.71M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIP
Chartwell Investment Partners
Berywn,
Pennsylvania
|
-$8.82M |
| 2 |
BIP
Brandes Investment Partners
La Jolla,
California
|
-$8.76M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$6.2M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$4.24M |
| 5 |
JGC
J. Goldman & Co
New York
|
-$3.85M |
EGRX Hedge Fund Activity: Q1 2022 in Review
160 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q1 2022, worth a combined $555M — down 3.1% from $573M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of EGRX and 15 opened new positions — a net loss of 2 holders — while 66 trimmed existing stakes and 55 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $10.8M. The largest seller was Chartwell Investment Partners, exiting entirely with an estimated $8.82M sold.
- 160 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q1 2022, down from 162 in Q4 2021.
- Funds reported $555M of Eagle Pharmaceuticals, Inc. stock for Q1 2022, down 3.1% quarter-over-quarter.
- 15 funds opened new Eagle Pharmaceuticals, Inc. positions in Q1 2022 and 17 closed out, a net change of -2 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q1 2022 was Armistice Capital, an estimated $10.8M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q1 2022 was Chartwell Investment Partners, an estimated $8.82M sold.
Based on aggregated 13F filings for Q1 2022.